AHFTC Board Certification Review Early Bird Registration ends April 26

Accelerating Medicines Partnership® Heart Failure (AMP® HF) Program

HFSA is proud to collaborate with the Foundation for the National Institutes of Health (FNIH) and the National Heart, Lung, and Blood Institute (NHLBI) on the launch of the new Accelerating Medicines Partnership® Heart Failure (AMP® HF) Program, which was announced on September 29, 2022.

AMP® HF is focused on a major unmet need in cardiovascular health. It brings together partners from the public, private, and nonprofit sectors to investigate the syndrome of heart failure with preserved ejection fraction (HFpEF), which continues to stymie researchers and clinicians. Using cutting-edge technologies, including digital measurements and artificial intelligence analytic methods, AMP HF aims to alter the landscape of heart failure treatment by refining the classification of HFpEF to discovering better, more precise treatment options, thus improving the outlook for millions of patients around the world.